These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 29807937)
1. Quadrivalent human papillomavirus vaccination in girls and the risk of autoimmune disorders: the Ontario Grade 8 HPV Vaccine Cohort Study. Liu EY; Smith LM; Ellis AK; Whitaker H; Law B; Kwong JC; Farrington P; Lévesque LE CMAJ; 2018 May; 190(21):E648-E655. PubMed ID: 29807937 [TBL] [Abstract][Full Text] [Related]
2. Effect of human papillomavirus (HPV) vaccination on clinical indicators of sexual behaviour among adolescent girls: the Ontario Grade 8 HPV Vaccine Cohort Study. Smith LM; Kaufman JS; Strumpf EC; Lévesque LE CMAJ; 2015 Feb; 187(2):E74-E81. PubMed ID: 25487660 [TBL] [Abstract][Full Text] [Related]
3. Factors associated with initiation and completion of the quadrivalent human papillomavirus vaccine series in an Ontario cohort of grade 8 girls. Smith LM; Brassard P; Kwong JC; Deeks SL; Ellis AK; Lévesque LE BMC Public Health; 2011 Aug; 11():645. PubMed ID: 21838921 [TBL] [Abstract][Full Text] [Related]
4. Individual- and regional-level determinants of human papillomavirus (HPV) vaccine refusal: the Ontario Grade 8 HPV vaccine cohort study. Remes O; Smith LM; Alvarado-Llano BE; Colley L; Lévesque LE BMC Public Health; 2014 Oct; 14():1047. PubMed ID: 25297055 [TBL] [Abstract][Full Text] [Related]
5. A case-control study of quadrivalent human papillomavirus vaccine-associated autoimmune adverse events. Geier DA; Geier MR Clin Rheumatol; 2015 Jul; 34(7):1225-31. PubMed ID: 25535199 [TBL] [Abstract][Full Text] [Related]
6. Human papillomavirus vaccination and risk of autoimmune diseases: A large cohort study of over 2million young girls in France. Miranda S; Chaignot C; Collin C; Dray-Spira R; Weill A; Zureik M Vaccine; 2017 Aug; 35(36):4761-4768. PubMed ID: 28750853 [TBL] [Abstract][Full Text] [Related]
7. Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects. Grimaldi-Bensouda L; Guillemot D; Godeau B; Bénichou J; Lebrun-Frenay C; Papeix C; Labauge P; Berquin P; Penfornis A; Benhamou PY; Nicolino M; Simon A; Viallard JF; Costedoat-Chalumeau N; Courcoux MF; Pondarré C; Hilliquin P; Chatelus E; Foltz V; Guillaume S; Rossignol M; Abenhaim L; J Intern Med; 2014 Apr; 275(4):398-408. PubMed ID: 24206418 [TBL] [Abstract][Full Text] [Related]
8. Evidence of effective delivery of the human papillomavirus (HPV) vaccine through a publicly funded, school-based program: the Ontario Grade 8 HPV Vaccine Cohort Study. Lim WT; Sears K; Smith LM; Liu G; Lévesque LE BMC Public Health; 2014 Oct; 14():1029. PubMed ID: 25278003 [TBL] [Abstract][Full Text] [Related]
9. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. Arnheim-Dahlström L; Pasternak B; Svanström H; Sparén P; Hviid A BMJ; 2013 Oct; 347():f5906. PubMed ID: 24108159 [TBL] [Abstract][Full Text] [Related]
10. Adverse events following immunization in Ontario's female school-based HPV program. Harris T; Williams DM; Fediurek J; Scott T; Deeks SL Vaccine; 2014 Feb; 32(9):1061-6. PubMed ID: 24440208 [TBL] [Abstract][Full Text] [Related]
11. The early benefits of human papillomavirus vaccination on cervical dysplasia and anogenital warts. Smith LM; Strumpf EC; Kaufman JS; Lofters A; Schwandt M; Lévesque LE Pediatrics; 2015 May; 135(5):e1131-40. PubMed ID: 25917991 [TBL] [Abstract][Full Text] [Related]
12. Incidence of new-onset autoimmune disease in girls and women with pre-existing autoimmune disease after quadrivalent human papillomavirus vaccination: a cohort study. Grönlund O; Herweijer E; Sundström K; Arnheim-Dahlström L J Intern Med; 2016 Dec; 280(6):618-626. PubMed ID: 27478093 [TBL] [Abstract][Full Text] [Related]
13. Long-term study of a quadrivalent human papillomavirus vaccine. Ferris D; Samakoses R; Block SL; Lazcano-Ponce E; Restrepo JA; Reisinger KS; Mehlsen J; Chatterjee A; Iversen OE; Sings HL; Shou Q; Sausser TA; Saah A Pediatrics; 2014 Sep; 134(3):e657-65. PubMed ID: 25136050 [TBL] [Abstract][Full Text] [Related]
14. Quadrivalent human papillomavirus vaccine and autoimmune adverse events: a case-control assessment of the vaccine adverse event reporting system (VAERS) database. Geier DA; Geier MR Immunol Res; 2017 Feb; 65(1):46-54. PubMed ID: 27406735 [TBL] [Abstract][Full Text] [Related]
15. Human papillomavirus vaccination of adult women and risk of autoimmune and neurological diseases. Hviid A; Svanström H; Scheller NM; Grönlund O; Pasternak B; Arnheim-Dahlström L J Intern Med; 2018 Feb; 283(2):154-165. PubMed ID: 29044769 [TBL] [Abstract][Full Text] [Related]
16. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. Chao C; Klein NP; Velicer CM; Sy LS; Slezak JM; Takhar H; Ackerson B; Cheetham TC; Hansen J; Deosaransingh K; Emery M; Liaw KL; Jacobsen SJ J Intern Med; 2012 Feb; 271(2):193-203. PubMed ID: 21973261 [TBL] [Abstract][Full Text] [Related]
17. Quadrivalent human papillomavirus vaccination in boys and risk of autoimmune diseases, neurological diseases and venous thromboembolism. Frisch M; Besson A; Clemmensen KKB; Valentiner-Branth P; Mølbak K; Hviid A Int J Epidemiol; 2018 Apr; 47(2):634-641. PubMed ID: 29425361 [TBL] [Abstract][Full Text] [Related]
18. Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study. Leval A; Herweijer E; Ploner A; Eloranta S; Fridman Simard J; Dillner J; Young C; Netterlid E; Sparén P; Arnheim-Dahlström L J Natl Cancer Inst; 2013 Apr; 105(7):469-74. PubMed ID: 23486550 [TBL] [Abstract][Full Text] [Related]
19. Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males. Bergman H; Buckley BS; Villanueva G; Petkovic J; Garritty C; Lutje V; Riveros-Balta AX; Low N; Henschke N Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31755549 [TBL] [Abstract][Full Text] [Related]
20. Early impact of Ontario's human papillomavirus (HPV) vaccination program on anogenital warts (AGWs): A population-based assessment. Guerra FM; Rosella LC; Dunn S; Wilson SE; Chen C; Deeks SL Vaccine; 2016 Sep; 34(39):4678-4683. PubMed ID: 27527815 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]